EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

Search

Sanofi SA

Atidarymo kaina

SektoriusSveikatos priežiūra

99.19 -3.47

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

97.94

Max

103.24

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.3B

499M

Pardavimai

-6.5B

7.6B

P/E

Sektoriaus vid.

23.216

63.778

Pelnas, tenkantis vienai akcijai

1.31

Dividendų pajamingumas

3.79

Pelno marža

6.539

Darbuotojai

82,878

EBITDA

-3.7B

563M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+13.01% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.79%

2.39%

Kitas uždarbis

2025-04-24

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-6B

125B

Ankstesnė atidarymo kaina

102.66

Ankstesnė uždarymo kaina

99.19

Naujienos nuotaikos

By Acuity

33%

67%

96 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Sanofi SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-20 06:43; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

2025-02-05 13:41; UTC

Uždarbis

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

2025-02-05 07:10; UTC

Uždarbis

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

2025-02-05 06:39; UTC

Uždarbis

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

2025-03-26 06:19; UTC

Rinkos pokalbiai
Uždarbis

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

2025-03-25 10:08; UTC

Rinkos pokalbiai

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

2025-03-20 09:00; UTC

Svarbiausios naujienos

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

2025-03-20 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Deal Seeks to Broaden Immunology Pipeline

2025-03-20 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

2025-03-20 06:04; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Pay $600M Upfront

2025-03-20 06:02; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

2025-03-20 06:00; UTC

Įsigijimai, susijungimai, perėmimai

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

2025-03-18 09:33; UTC

Karštos akcijos

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

2025-03-17 23:00; UTC

Svarbiausios naujienos

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

2025-03-13 09:50; UTC

Uždarbis

Santander Approves Final Cash Dividend Per Share of EUR11 cents

2025-03-13 09:49; UTC

Uždarbis

Santander Increased 2024 Cash Payments by 19%

2025-02-24 08:56; UTC

Rinkos pokalbiai
Uždarbis

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

2025-02-24 08:30; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

2025-02-19 06:35; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

2025-02-19 06:34; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

2025-02-19 06:34; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

2025-02-19 06:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Remain Significant Shareholder in Opella Consumer Business

2025-02-19 06:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

2025-02-19 06:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: This Follows Completion of Required Social and Corporate Procedures

2025-02-19 06:32; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

2025-02-19 06:31; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi, CD&R Sign Opella Share Purchase Agreement

2025-02-14 10:55; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

2025-02-05 07:48; UTC

Rinkos pokalbiai
Uždarbis

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

2025-02-05 06:01; UTC

Uždarbis

Santander: Franco Joins Getnet From Canadian Fintech Company Nuvei

2025-02-05 06:01; UTC

Uždarbis

Santander: Getnet's Current CEO, Kush Saxena, Has Decided to Resign

Akcijų palyginimas

Kainos pokytis

Sanofi SA Prognozė

Kainos tikslas

By TipRanks

13.01% į viršų

12 mėnesių prognozė

Vidutinis 115.177 EUR  13.01%

Aukščiausias 125 EUR

Žemiausias 92 EUR

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

9

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

101.1 / 103.88Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

96 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.